1. A 64-year-old man with HFrEF (heart failure with reduced ejection fraction; LVEF [left ventricular ejection fraction] 28%) returns to the heart failure clinic 4 months after being transitioned from enalapril to sacubitril-valsartan (a combination neprilysin inhibitor and angiotensin receptor blocker). He reports improved functional status and has no peripheral edema. The clinician wants to order a natriuretic peptide level to assess volume status and guide ongoing management. His creatinine is 1.3 mg/dL and eGFR (estimated glomerular filtration rate) is 54 mL/min/1.73 m². Which of the following is the most appropriate natriuretic peptide biomarker to order for longitudinal monitoring in this patient?
A) BNP (B-type natriuretic peptide), because its shorter half-life of approximately 20 minutes provides a more dynamic and real-time reflection of acute changes in cardiac filling pressures than NT-proBNP, making it superior for detecting early volume accumulation before clinical signs develop.
B) BNP, because sacubitril-valsartan reduces myocardial wall stress through RAAS blockade, causing BNP synthesis to fall proportionally; the resulting low BNP level in treated patients accurately reflects improved hemodynamics and is unaffected by neprilysin inhibition at the standard therapeutic dose.
C) NT-proBNP (N-terminal pro-B-type natriuretic peptide), because neprilysin inhibition by sacubitril impairs BNP degradation and causes BNP to accumulate artifactually regardless of true cardiac filling pressure, whereas NT-proBNP is not a neprilysin substrate and continues to reflect myocardial wall stress; serial NT-proBNP values therefore remain valid for tracking volume status and therapeutic response in sacubitril-valsartan-treated patients.
D) Either BNP or NT-proBNP can be used interchangeably in this patient because sacubitril-valsartan affects neither biomarker's plasma concentration; the choice between them should be based solely on the local laboratory's reference range calibration and assay cost rather than on pharmacokinetic considerations.
E) NT-proBNP should be avoided in this patient because his reduced eGFR of 54 mL/min/1.73 m² causes NT-proBNP retention through impaired renal tubular secretion, producing falsely elevated values that cannot be interpreted in the context of sacubitril-valsartan therapy; BNP is preferred in all patients with eGFR below 60 mL/min/1.73 m².
ANSWER: C
Rationale:
Sacubitril, after in vivo hydrolysis to its active metabolite LBQ657, inhibits neprilysin (neutral endopeptidase 24.11), which is the primary enzyme responsible for BNP degradation in the circulation; when neprilysin is inhibited, BNP clearance is impaired and circulating BNP accumulates to levels that reflect enzyme inhibition rather than true ventricular wall stress or filling pressure, rendering BNP unreliable as a monitoring biomarker in sacubitril-valsartan-treated patients; NT-proBNP, by contrast, is not a neprilysin substrate and is cleared through renal filtration and natriuretic peptide clearance receptor-mediated pathways that are unaffected by sacubitril, so NT-proBNP levels continue to correlate with myocardial wall stress and provide a valid longitudinal monitoring signal even during neprilysin inhibition.
Option A: Option A is incorrect because BNP's shorter half-life is irrelevant when its baseline concentration is pharmacologically elevated by neprilysin inhibition independent of filling pressure; a faster-responding biomarker that has lost its relationship to the underlying hemodynamic variable being measured provides no monitoring benefit over a slower but valid biomarker.
Option B: Option B is incorrect because while sacubitril-valsartan does reduce myocardial wall stress and may lower the rate of proBNP synthesis over time, the dominant pharmacokinetic effect on circulating BNP is impaired degradation from neprilysin inhibition, which drives BNP levels upward regardless of any synthesis reduction; the net result is artifactual BNP elevation, not a reliably low BNP level.
Option D: Option D is incorrect because BNP and NT-proBNP are not interchangeable in sacubitril-valsartan-treated patients; neprilysin inhibition specifically and substantially affects BNP clearance while leaving NT-proBNP clearance unchanged, creating a pharmacokinetically important difference between the two assays that is directly relevant to monitoring in this clinical context.
Option E: Option E is incorrect because while reduced eGFR does elevate NT-proBNP levels through impaired renal filtration, this does not invalidate NT-proBNP for monitoring on sacubitril-valsartan — the clinician simply interprets serial values in the context of stable renal function; furthermore, BNP is not the preferred biomarker in reduced eGFR patients on sacubitril-valsartan, as neprilysin inhibition makes BNP unreliable regardless of renal function.
2. A 72-year-old woman with ischemic cardiomyopathy is admitted with acute decompensated heart failure. Her blood pressure on arrival is 96/60 mmHg, heart rate 108 bpm, respiratory rate 26 breaths/min, and oxygen saturation 88% on room air. Chest radiograph confirms bilateral pulmonary edema. She has received intravenous furosemide with incomplete diuretic response. The attending physician considers adding nesiritide (recombinant BNP; a vasodilator acting via NPR-A-mediated cGMP production) to reduce filling pressures. Which of the following best characterizes the primary risk of nesiritide in this specific patient and the appropriate prescribing threshold?
A) The primary risk of nesiritide in this patient is renal tubular toxicity from cGMP-mediated afferent arteriolar constriction; nesiritide should be avoided whenever serum creatinine exceeds 1.5 mg/dL regardless of blood pressure, as renal injury is the dominant safety concern in the acute decompensated heart failure setting.
B) The primary risk of nesiritide is ventricular proarrhythmia through NPR-A-mediated calcium overload in cardiomyocytes; it is contraindicated in patients with ischemic cardiomyopathy because cGMP accumulation sensitizes scarred ventricular myocardium to triggered automaticity and reentrant arrhythmia.
C) The primary risk of nesiritide is hypertensive crisis from initial receptor desensitization at low perfusion pressures; a blood pressure of 96/60 mmHg places this patient in the optimal dosing range for nesiritide, as vasodilation is most beneficial when the arteries are already partially constricted from sympathetic activation.
D) The primary risk of nesiritide is respiratory depression through central NPR-B (natriuretic peptide receptor B) activation in the brainstem; it should be withheld whenever the respiratory rate exceeds 20 breaths/min because brainstem cGMP accumulation may suppress the hypoxic ventilatory drive in patients with acute pulmonary edema.
E) The primary risk of nesiritide in this patient is clinically significant hypotension; nesiritide is formally contraindicated when systolic blood pressure is below 90 mmHg, and at a systolic of 96 mmHg this patient is marginally above the contraindication threshold but remains at high risk for a further blood pressure drop during infusion, requiring close hemodynamic monitoring and a low threshold to hold the infusion if systolic falls below 90 mmHg.
ANSWER: E
Rationale:
Nesiritide exerts its hemodynamic effects by binding NPR-A and generating cGMP, which causes both venodilation (reducing preload) and arterial vasodilation (reducing SVR and afterload); because this vasodilatory mechanism is not blood-pressure-selective, patients with already-marginal perfusion pressures are at high risk for clinically significant hypotension during infusion; nesiritide is formally contraindicated when systolic blood pressure is below 90 mmHg because vasodilation at that level would compromise coronary and end-organ perfusion; this patient at 96 mmHg is above the contraindication threshold but only marginally so, placing her in a high-risk zone where close hemodynamic monitoring is mandatory and the infusion should be held immediately if systolic blood pressure falls further — illustrating that the labeled contraindication defines the boundary, but clinical judgment requires anticipating hemodynamic fragility in patients near that boundary.
Option A: Option A is incorrect because renal tubular toxicity from afferent arteriolar constriction is not the mechanism of nesiritide's renal adverse effects; nesiritide's effect on renal function is primarily through systemic hypotension reducing renal perfusion pressure, not through direct tubular toxicity, and creatinine elevation is not the basis for the primary prescribing threshold in this scenario.
Option B: Option B is incorrect because nesiritide does not produce ventricular proarrhythmia through cGMP-mediated calcium overload; proarrhythmia is not a recognized safety signal for nesiritide, and NPR-A-cGMP signaling in cardiomyocytes does not sensitize ischemic myocardium to triggered automaticity; ischemic cardiomyopathy is not a contraindication to nesiritide.
Option C: Option C is incorrect because nesiritide does not produce an initial hypertensive crisis from receptor desensitization; it consistently produces vasodilation from the onset of infusion, and a systolic of 96 mmHg does not represent an optimal dosing range — it represents a borderline-safe pressure at which the risk of the drug's primary adverse effect (hypotension) is substantially elevated.
Option D: Option D is incorrect because nesiritide does not act on NPR-B in the brainstem to suppress ventilatory drive; NPR-B is the receptor for CNP (C-type natriuretic peptide), not for nesiritide (recombinant BNP), and respiratory depression through central natriuretic peptide receptor activation is not a recognized pharmacological effect or adverse event associated with nesiritide.
3. A 78-year-old woman presents to the emergency department with 3 days of progressive dyspnea, orthopnea, and bilateral lower-extremity edema. She has a history of hypertension and atrial fibrillation. Vital signs: blood pressure 162/94 mmHg, heart rate 88 bpm (irregularly irregular), oxygen saturation 90% on room air. An NT-proBNP level returns at 2,100 pg/mL. The emergency physician covering the shift is unfamiliar with age-adjusted NT-proBNP thresholds and states that the result is "borderline" because it falls below the 2,500 pg/mL value she recalls as the diagnostic cutoff. Which of the following correctly applies the age-stratified NT-proBNP diagnostic threshold to this patient?
A) The NT-proBNP result of 2,100 pg/mL exceeds the age-appropriate rule-in threshold for this patient; validated age-stratified cutoffs place the rule-in threshold at 1,800 pg/mL for patients older than 75 years, reflecting the physiologically higher baseline NT-proBNP concentrations in elderly individuals due to reduced renal clearance and increased cardiac fibrosis, and this result therefore strongly supports acute heart failure as the etiology of her dyspnea.
B) The NT-proBNP result of 2,100 pg/mL falls in the indeterminate zone for this patient's age; the validated rule-in threshold for patients over 75 years is 2,500 pg/mL, and values between 1,800 and 2,500 pg/mL in elderly patients require echocardiographic confirmation before heart failure can be diagnosed with confidence.
C) NT-proBNP thresholds are not age-adjusted in current diagnostic guidelines; the single validated rule-in cutoff of 900 pg/mL applies to all adults regardless of age, and a result of 2,100 pg/mL substantially exceeds this threshold and is diagnostic of acute heart failure in any adult patient irrespective of age-related physiological differences.
D) The NT-proBNP result of 2,100 pg/mL should be interpreted cautiously in this patient because atrial fibrillation independently elevates NT-proBNP by approximately 50% above the expected value for heart failure alone; the age-adjusted effective threshold in patients with atrial fibrillation over 75 years is therefore 2,700 pg/mL, placing this result below the corrected diagnostic cutoff.
E) NT-proBNP thresholds decrease with advancing age because older patients have lower cardiac reserve and release less natriuretic peptide per unit of wall stress; the correct threshold for patients over 75 years is 450 pg/mL, making a result of 2,100 pg/mL markedly elevated and diagnostic of severe, advanced decompensated heart failure requiring immediate intensive care admission.
ANSWER: A
Rationale:
NT-proBNP diagnostic thresholds for acute dyspnea evaluation are age-stratified based on the validated PRIDE and international confirmatory studies: the rule-in cutoff is 450 pg/mL for patients under 50 years, 900 pg/mL for patients aged 50–75 years, and 1,800 pg/mL for patients older than 75 years; the higher threshold in elderly patients reflects the physiologically elevated NT-proBNP baseline in this age group, attributable to age-related reductions in renal filtration rate, increased ventricular fibrosis and stiffness, and the higher prevalence of subclinical cardiac dysfunction; this patient at age 78 with an NT-proBNP of 2,100 pg/mL clearly exceeds the 1,800 pg/mL age-appropriate rule-in threshold, strongly supporting acute heart failure as the cause of her dyspnea and making the covering physician's characterization of the result as "borderline" incorrect.
Option B: Option B is incorrect because the rule-in threshold for patients over 75 years is 1,800 pg/mL, not 2,500 pg/mL; 2,100 pg/mL exceeds this validated threshold and the result is not indeterminate; no validated "indeterminate zone" between 1,800 and 2,500 pg/mL exists in the age-stratified NT-proBNP diagnostic algorithm for patients in this age group.
Option C: Option C is incorrect because NT-proBNP thresholds are indeed age-stratified in current diagnostic practice; a single 900 pg/mL cutoff for all adults would misclassify many elderly patients whose NT-proBNP is physiologically elevated above this level in the absence of acute heart failure, producing false-positive diagnoses; the three-tier age-stratified system was specifically designed to preserve diagnostic specificity across the age spectrum.
Option D: Option D is incorrect because there is no validated guideline-endorsed atrial fibrillation correction factor applied to NT-proBNP thresholds; while atrial fibrillation can contribute to NT-proBNP elevation through atrial stretch and tachycardia-related wall stress, the diagnostic thresholds are applied as published without a multiplicative AF adjustment factor, and a 2,700 pg/mL "corrected" threshold for AF patients over 75 years is not supported by current evidence or practice guidelines.
Option E: Option E is incorrect because it inverts the direction of age-related threshold adjustment; NT-proBNP thresholds increase with advancing age (not decrease), and the 450 pg/mL threshold applies to the youngest age group (under 50 years), not to patients over 75 years; attributing a lower threshold to elderly patients would dramatically reduce specificity in this age group.
4. A 55-year-old man with stage III non-small cell lung cancer receives his first cycle of cisplatin-based chemotherapy. He is given ondansetron (a 5-HT3 [serotonin type 3] receptor antagonist) and dexamethasone on day 1 for antiemetic prophylaxis. He tolerates day 1 well with minimal nausea. On day 3, he calls the oncology clinic reporting severe nausea and two vomiting episodes that morning. He denies fever, abdominal pain, or diarrhea. He took his prescribed ondansetron on days 2 and 3 as directed. Which of the following best identifies the pharmacological gap in his antiemetic regimen and the drug class that would have most effectively addressed it?
A) The pharmacological gap is inadequate dopamine D2 receptor blockade in the chemoreceptor trigger zone (CTZ; a chemosensory area in the area postrema of the brainstem); adding a D2 antagonist such as prochlorperazine on days 1 through 3 would have addressed the late-phase emesis driven by dopamine accumulation after cisplatin-induced enterochromaffin cell turnover.
B) The pharmacological gap is inadequate histamine H1 receptor blockade in the vestibular nucleus; cisplatin activates the vestibulocochlear nerve through its ototoxic mechanism and stimulates histamine release in the inner ear on days 2 and 3, producing a motion-sickness-like delayed emesis that requires meclizine or diphenhydramine for prevention.
C) The pharmacological gap is inadequate gastric prokinesis; cisplatin causes delayed gastroparesis through enteric neuronal damage on day 2 and 3, and the addition of metoclopramide (a D2 antagonist and prokinetic agent) as a scheduled regimen on days 2 and 3 would have prevented the gastric stasis that drives late-phase nausea after highly emetogenic chemotherapy.
D) The pharmacological gap is the absence of NK1 receptor (neurokinin-1 receptor; the primary receptor for substance P, an 11-amino-acid neuropeptide released centrally and peripherally after chemotherapy-induced cellular injury) antagonism; the delayed phase of CINV (chemotherapy-induced nausea and vomiting; occurring 24–120 hours after administration) is driven primarily by substance P rather than serotonin, and 5-HT3 antagonists such as ondansetron become less effective after the first 24 hours as serotonin signaling declines; aprepitant, an NK1 antagonist, added to the regimen on days 1 through 3 would have specifically addressed this gap.
E) The pharmacological gap is the use of ondansetron (a first-generation 5-HT3 antagonist) rather than palonosetron (a second-generation 5-HT3 antagonist with higher receptor binding affinity and a half-life of approximately 40 hours); substituting palonosetron for ondansetron on day 1 would have provided continuous 5-HT3 receptor blockade through day 3 through serotonin pathway coverage alone, without the need to add a drug from any other antiemetic class.
ANSWER: D
Rationale:
CINV is divided into acute phase (0–24 hours post-chemotherapy), driven predominantly by serotonin released from cisplatin-damaged enterochromaffin cells activating 5-HT3 receptors on vagal afferents — making 5-HT3 antagonists such as ondansetron effective in this window — and delayed phase (24–120 hours), driven predominantly by substance P activating NK1 receptors centrally in the nucleus tractus solitarius and area postrema and peripherally in the enteric nervous system as serotonin-mediated signaling declines; this patient's pattern — well-controlled emesis on day 1 followed by breakthrough nausea and vomiting on day 3 despite continued ondansetron — is the clinical signature of inadequately treated delayed-phase CINV; aprepitant (125 mg day 1, 80 mg days 2–3), an NK1 receptor antagonist, is the standard addition to 5-HT3 antagonist plus dexamethasone for highly emetogenic chemotherapy specifically because it addresses this substance P-mediated delayed phase that serotonin pathway blockade cannot cover.
Option A: Option A is incorrect because while dopamine D2 antagonists have antiemetic activity in the area postrema, delayed-phase CINV after cisplatin is not driven primarily by dopamine accumulation after enterochromaffin cell turnover; the dominant delayed-phase mediator is substance P at NK1 receptors, and adding a D2 antagonist as the primary pharmacological intervention for delayed CINV does not address the mechanistic gap as precisely as NK1 antagonism.
Option B: Option B is incorrect because cisplatin-induced ototoxicity is a cochlear toxicity mechanism involving hair cell damage, not a brainstem histamine-releasing emesis mechanism; delayed CINV after cisplatin is not a vestibular or motion-sickness-type phenomenon, and H1 antihistamines are not indicated for delayed-phase CINV prophylaxis in highly emetogenic chemotherapy regimens.
Option C: Option C is incorrect because while cisplatin can impair gastrointestinal motility, delayed gastroparesis is not the primary mechanism of delayed CINV after cisplatin; the substance P-NK1 receptor pathway is the established pharmacological target for delayed-phase emesis, and metoclopramide as a prokinetic is not the recommended prophylactic intervention for the delayed phase of highly emetogenic chemotherapy-induced CINV per ASCO guidelines.
Option E: Option E is incorrect because while palonosetron's longer half-life and higher receptor binding affinity do provide superior acute-phase coverage compared with first-generation 5-HT3 antagonists, substituting palonosetron for ondansetron alone would not have prevented delayed-phase CINV; both are 5-HT3 antagonists and neither addresses the substance P-NK1 receptor pathway that drives emesis on days 2 through 5, meaning that the fundamental pharmacological gap of absent NK1 antagonism would remain regardless of which 5-HT3 antagonist is used.
5. A 61-year-old woman with ovarian cancer and atrial fibrillation is anticoagulated with warfarin, with a stable INR (international normalized ratio; a standardized measure of anticoagulant effect) of 2.3. She begins her first cycle of carboplatin-based chemotherapy. Her oncologist adds aprepitant (125 mg day 1, 80 mg days 2–3) as part of the antiemetic regimen. No other medications are changed. At her clinic visit 10 days later, her INR is 1.6. Which of the following best explains the mechanism responsible for this change in INR?
A) Aprepitant inhibits CYP3A4, the hepatic enzyme that metabolizes R-warfarin (the less pharmacologically active enantiomer); reduced R-warfarin clearance increases total warfarin plasma concentrations and would be expected to raise the INR rather than lower it, suggesting that a non-pharmacological explanation such as dietary vitamin K intake is responsible for the INR decline seen in this patient.
B) Aprepitant induces CYP2C9 (cytochrome P450 2C9; the primary hepatic enzyme responsible for oxidative metabolism of S-warfarin, the more pharmacologically active enantiomer); CYP2C9 induction accelerates S-warfarin clearance, reducing its plasma concentration and anticoagulant effect; the INR decline is delayed relative to aprepitant initiation because enzyme induction requires new protein synthesis over several days to reach maximum effect, consistent with the 10-day interval observed in this patient.
C) Aprepitant induces intestinal P-glycoprotein (P-gp; an efflux transporter expressed in the gut epithelium), reducing oral warfarin bioavailability by increasing its efflux back into the intestinal lumen before absorption; the net effect is lower systemic warfarin exposure despite unchanged dosing, producing the observed INR decline without any alteration in hepatic warfarin metabolism.
D) Aprepitant competes with warfarin for binding to plasma albumin, displacing warfarin from protein binding sites and increasing the free (unbound) warfarin fraction; the increased free warfarin is rapidly redistributed into adipose tissue, reducing the plasma concentration available for anticoagulant activity and producing the observed INR decline within 24 hours of the first aprepitant dose.
E) Aprepitant inhibits CYP2C9, reducing S-warfarin metabolism and causing S-warfarin plasma concentrations to rise; the expected consequence is INR elevation, not decline; the observed subtherapeutic INR of 1.6 therefore indicates that the patient has been non-adherent to her warfarin regimen independent of any aprepitant drug interaction.
ANSWER: B
Rationale:
Aprepitant is a substrate, weak inhibitor, and inducer of multiple cytochrome P450 enzymes; in the context of warfarin co-administration, the clinically dominant interaction is CYP2C9 induction — aprepitant upregulates CYP2C9 expression in hepatocytes through nuclear receptor-mediated mechanisms, increasing the rate of S-warfarin oxidative metabolism; S-warfarin is the pharmacologically more potent enantiomer of the racemic warfarin formulation and is responsible for the majority of the anticoagulant effect, so accelerated S-warfarin clearance reduces total anticoagulant activity and the INR falls; enzyme induction is not immediate — it requires new CYP2C9 enzyme protein synthesis over several days, explaining why the INR decline is apparent at 10 days rather than 24–48 hours after aprepitant initiation; this interaction is noted in the aprepitant prescribing information, which specifically recommends close INR monitoring in patients on warfarin for 7–14 days following aprepitant use.
Option A: Option A is incorrect because while aprepitant does inhibit CYP3A4 (and R-warfarin is a CYP3A4 substrate), the dominant clinical drug interaction affecting the INR is CYP2C9 induction causing S-warfarin clearance acceleration, which lowers rather than raises the INR; the net direction of the aprepitant-warfarin interaction is a falling INR, consistent with what is observed in this patient, not a rising one.
Option C: Option C is incorrect because aprepitant does not significantly induce intestinal P-glycoprotein in a manner that reduces warfarin bioavailability; warfarin is not a primary P-gp substrate, and reduced intestinal absorption is not the established mechanism of the aprepitant-warfarin interaction; the pharmacokinetic interaction occurs at the level of hepatic CYP2C9 enzyme induction, not intestinal efflux transport.
Option D: Option D is incorrect because plasma protein binding displacement is not the mechanism of the aprepitant-warfarin interaction; while both drugs are highly protein-bound, displacement interactions are generally not clinically significant because the transient increase in free drug concentration is rapidly compensated by increased volume of distribution and enhanced clearance; an INR change attributable to protein binding displacement would occur within hours, not 10 days, and this mechanism is not supported by aprepitant's known pharmacokinetic profile.
Option E: Option E is incorrect because aprepitant induces (not inhibits) CYP2C9, so the direction of the drug interaction is increased S-warfarin metabolism and falling INR, exactly as observed; the INR decline in this patient is pharmacologically explained by CYP2C9 induction and does not require invoking non-adherence as an alternative explanation.
6. A 38-year-old woman is diagnosed with idiopathic pulmonary arterial hypertension (PAH; a progressive obliterative vasculopathy of the pulmonary circulation), WHO Functional Class II, with a mean pulmonary arterial pressure of 42 mmHg and a pulmonary vascular resistance of 7.2 Wood units on right heart catheterization. She tests negative on acute vasoreactivity testing. She is started on ambrisentan (an ERA [endothelin receptor antagonist] that blocks ETA receptors [endothelin type A receptors], reducing endothelin-1-mediated pulmonary vasoconstriction and smooth muscle proliferation) as monotherapy. Six months later she remains in WHO Functional Class II but has not improved her 6-minute walk distance and her NT-proBNP has risen from 280 to 390 pg/mL. Which of the following represents the most guideline-concordant next pharmacological step?
A) Transition from ambrisentan (selective ETA antagonist) to bosentan (dual ETA/ETB [endothelin type A/type B receptor] antagonist) to achieve more complete endothelin pathway blockade; dual receptor antagonism has been shown in randomized trials to produce superior pulmonary hemodynamic outcomes compared with selective ETA antagonism in PAH patients who have not responded adequately to monotherapy with a selective agent.
B) Add intravenous epoprostenol (a prostacyclin analogue that activates IP receptors [prostacyclin receptors] on pulmonary vascular smooth muscle, producing vasodilation and antiproliferative effects) because failing ERA monotherapy in a WHO FC II patient indicates insufficient disease control requiring immediate escalation to continuous intravenous prostacyclin therapy, which is the most effective pharmacological intervention available for PAH.
C) Add tadalafil (a PDE5 inhibitor [phosphodiesterase type 5 inhibitor] that prevents cGMP [cyclic guanosine monophosphate] degradation in pulmonary vascular smooth muscle, augmenting nitric oxide-mediated vasodilation) to the existing ambrisentan; initial combination therapy with an ERA plus a PDE5 inhibitor is the evidence-based standard for treatment-naive and inadequately responding PAH patients, supported by the AMBITION trial demonstrating superior clinical outcomes with upfront ambrisentan-tadalafil combination versus either agent as monotherapy.
D) Add riociguat (a soluble guanylyl cyclase stimulator that increases cGMP production independent of nitric oxide availability) to the existing ambrisentan; the combination of ERA plus riociguat is the preferred second agent in PAH patients failing ERA monotherapy because riociguat and PDE5 inhibitors share the cGMP pathway and are pharmacodynamically equivalent, making riociguat the safer and more evidence-based choice when ambrisentan monotherapy proves insufficient.
E) Discontinue ambrisentan and substitute selexipag (an oral IP receptor agonist that mimics prostacyclin's vasodilatory and antiproliferative effects via the Gs-cAMP [cyclic adenosine monophosphate] pathway) as monotherapy; the GRIPHON trial demonstrated that selexipag monotherapy produces superior morbidity and mortality outcomes compared with ERA monotherapy in WHO FC II PAH, establishing prostacyclin receptor agonism as the preferred pharmacological class for initial management of newly diagnosed PAH.
ANSWER: C
Rationale:
Contemporary PAH guidelines (ESC/ERS 2022 and AHA/ACC expert consensus) recommend ERA plus PDE5 inhibitor combination as the evidence-based treatment strategy for most WHO Functional Class II and III PAH patients, whether initiated upfront or after inadequate response to monotherapy; the AMBITION trial randomized treatment-naive PAH patients to ambrisentan plus tadalafil versus ambrisentan alone or tadalafil alone and demonstrated that the combination significantly reduced the primary composite endpoint of clinical failure events compared with either monotherapy arm; in this patient who has failed to improve on ambrisentan monotherapy over 6 months — evidenced by stable but not improved 6-minute walk distance and a rising NT-proBNP — adding a PDE5 inhibitor such as tadalafil to achieve dual-pathway pharmacological targeting of both the endothelin (ERA) and nitric oxide/cGMP (PDE5i) pathways represents the guideline-concordant escalation strategy.
Option A: Option A is incorrect because transitioning from selective ETA antagonism (ambrisentan) to dual ETA/ETB antagonism (bosentan) is not the recommended strategy for ERA monotherapy inadequate response; no randomized trial has demonstrated superiority of dual over selective ETA antagonism in terms of clinical outcomes in this population, and the AMBITION trial evidence supports adding a pharmacologically distinct pathway agent (PDE5i) rather than switching within the endothelin antagonist class.
Option B: Option B is incorrect because intravenous epoprostenol is reserved for advanced WHO Functional Class III–IV disease or as rescue therapy in patients with rapidly progressive PAH; a WHO FC II patient with stable functional class and modestly rising NT-proBNP does not meet the clinical threshold for immediate escalation to continuous intravenous prostacyclin therapy, and the associated complexity, infection risk, and catheter management burden make IV epoprostenol an inappropriate next step at this stage.
Option D: Option D is incorrect because riociguat (a soluble guanylyl cyclase stimulator) and PDE5 inhibitors are specifically contraindicated in combination; both agents increase cGMP through different mechanisms (riociguat by stimulating cGMP synthesis, PDE5 inhibitors by preventing cGMP degradation), and their combination produces severe, potentially fatal hypotension — this combination is formally contraindicated in the riociguat prescribing information; while riociguat combined with ERA is an approved strategy, the framing that it is preferred over ERA plus PDE5i is not supported by comparative evidence.
Option E: Option E is incorrect because selexipag is approved as add-on therapy to ERA and/or PDE5 inhibitor background therapy, not as a monotherapy replacement for ERA; the GRIPHON trial evaluated selexipag added to existing ERA or PDE5 inhibitor therapy, and its results do not support substituting ERA monotherapy with selexipag monotherapy as a preferred initial management strategy.
7. A 58-year-old man with decompensated heart failure is admitted with hypervolemic hyponatremia; his serum sodium on admission is 126 mEq/L. He is started on tolvaptan (a selective vasopressin V2 receptor antagonist that produces aquaresis [excretion of electrolyte-free water] by blocking AVP [arginine vasopressin]-mediated AQP2 [aquaporin-2] insertion in the renal collecting duct). Repeat serum sodium levels are ordered every 6 hours per protocol. At 24 hours, his serum sodium has risen to 139 mEq/L. The nurse asks whether this represents successful treatment. Which of the following best characterizes the clinical significance of this sodium correction rate?
A) The sodium correction rate of 13 mEq/L over 24 hours exceeds the established safety ceiling of 10–12 mEq/L per 24 hours and represents overcorrection, placing this patient at risk for osmotic demyelination syndrome (ODS; a potentially irreversible neurological injury caused by overly rapid re-establishment of cerebral osmolarity in chronically hyponatremic patients); tolvaptan should be held and free water administered to slow or partially reverse the sodium correction rate.
B) The sodium correction rate of 13 mEq/L over 24 hours is within the acceptable therapeutic range for tolvaptan-mediated aquaresis; the 10–12 mEq/L ceiling applies only to hypertonic saline administration for acute symptomatic hyponatremia, not to the gentler aquaretic mechanism of V2 antagonism, which does not carry the same risk of osmotic demyelination due to its non-electrolyte correction mechanism.
C) The sodium correction of 13 mEq/L over 24 hours indicates that the tolvaptan dose should be increased to capitalize on the robust aquaretic response; the goal of tolvaptan therapy in hypervolemic hyponatremia is to normalize serum sodium to 140–145 mEq/L as rapidly as possible to reduce the duration of cerebral hypo-osmolarity and minimize the risk of hyponatremic encephalopathy.
D) The sodium correction rate of 13 mEq/L over 24 hours is clinically appropriate because heart failure patients with hypervolemic hyponatremia are not at risk for osmotic demyelination syndrome; ODS occurs exclusively in euvolemic hyponatremia due to SIADH (syndrome of inappropriate ADH secretion), and the higher total body sodium content in hypervolemic patients provides a physiological buffer against demyelination regardless of correction rate.
E) The sodium correction rate of 13 mEq/L over 24 hours is adequate but represents the maximum safe rate for tolvaptan therapy; the tolvaptan dose should be maintained at its current level without adjustment because the 10–12 mEq/L guideline represents a target range rather than a ceiling, and values of 13 mEq/L fall within acceptable variation given individual patient variability in aquaretic response.
ANSWER: A
Rationale:
The established safety ceiling for serum sodium correction in chronic hyponatremia is 10–12 mEq/L per 24 hours, a limit derived from clinical observations and pathophysiological studies showing that chronically hyponatremic patients adapt to low serum osmolality through reduction of brain organic osmolytes over days; when sodium is corrected faster than the brain can re-accumulate these osmolytes, rapid osmotic shifts cause water to exit brain cells, shrinking neurons and causing demyelination of myelin sheaths — particularly in the central pons (central pontine myelinolysis) and extrapontine sites — producing ODS, which can manifest as dysarthria, dysphagia, flaccid paralysis, locked-in syndrome, or death; a correction rate of 13 mEq/L in 24 hours exceeds this ceiling and constitutes overcorrection regardless of the mechanism used; the tolvaptan label specifies monitoring serum sodium every 6 hours precisely to detect and interrupt overcorrection before it causes neurological injury, and the appropriate response is to hold tolvaptan and administer free water orally or as D5W intravenously to slow the rate.
Option B: Option B is incorrect because the 10–12 mEq/L per 24-hour ceiling applies universally to all methods of hyponatremia correction, including aquaresis by V2 antagonism; the mechanism of sodium correction (electrolyte infusion versus free water removal) does not change the brain's vulnerability to osmotic demyelination when correction is too rapid, and tolvaptan is explicitly required to be initiated in hospital precisely to enable monitoring and prevention of this complication.
Option C: Option C is incorrect because rapid normalization to 140–145 mEq/L is not the therapeutic goal in chronic hyponatremia; the objective is controlled correction within the safety ceiling to minimize ODS risk, and a target of rapid normalization would place the patient at severe risk of irreversible neurological injury; tolvaptan therapy in hypervolemic hyponatremia aims to raise sodium gradually into a safe range, not to normalize it as quickly as possible.
Option D: Option D is incorrect because hypervolemic hyponatremia does not protect against ODS; the risk of osmotic demyelination from overly rapid sodium correction is present in hypervolemic (heart failure, cirrhosis), euvolemic (SIADH), and hypovolemic hyponatremia alike; total body sodium excess does not buffer against the cerebral osmotic stress produced by rapid sodium correction.
Option E: Option E is incorrect because 10–12 mEq/L per 24 hours is a ceiling, not a target range within which 13 mEq/L represents acceptable variation; exceeding this threshold by any amount increases the risk of ODS, and the appropriate clinical response to a rate of 13 mEq/L is intervention to slow correction, not continuation of the current tolvaptan dose.
8. A 52-year-old woman presents to the neurology clinic for management of moderate-to-severe migraine attacks occurring 3–4 times per month. Her migraines are associated with photophobia, phonophobia, and vomiting, and typically last 18–24 hours without treatment. Her medical history is significant for a myocardial infarction (STEMI [ST-elevation myocardial infarction]) 14 months ago, for which she underwent percutaneous coronary intervention and now takes aspirin, ticagrelor, atorvastatin, and metoprolol. She has never received migraine-specific therapy. The neurologist is considering acute migraine pharmacotherapy. Which of the following correctly identifies the appropriate drug class and agent for this patient's acute migraine attacks?
A) Sumatriptan, a 5-HT1B/1D agonist, is appropriate for this patient because its preferential activity at 5-HT1D receptors in the trigeminal ganglion produces analgesia without meaningful coronary vascular effects at standard oral doses; the coronary vasoconstriction associated with sumatriptan occurs only with the intravenous formulation and is not clinically relevant with the oral or subcutaneous route in patients with stable coronary disease managed with dual antiplatelet therapy.
B) Ergotamine, a non-selective serotonin receptor agonist with potent vasoconstriction, is the preferred agent for migraine patients with prior myocardial infarction because its duration of action allows a single dose to prevent migraine recurrence throughout the ictal period, reducing the total number of cardiovascular stress events associated with repeated acute migraine attacks.
C) Opioid analgesics such as butorphanol nasal spray are the recommended first-line acute migraine therapy for patients with ischemic heart disease because opioids do not interact with serotonin receptors, do not cause vasoconstriction, and provide reliable headache relief without cardiovascular risk; the coronary safety profile of opioids makes them superior to any vasoactive migraine-specific drug class in this population.
D) Dihydroergotamine (DHE) administered intranasally is the preferred acute treatment for this patient because its selective activity at 5-HT1B receptors in the cranial venous sinuses is restricted to low-capacitance venous beds and does not extend to the coronary arterial tree; published data from cardiac catheterization studies confirm that intranasal DHE does not alter coronary arterial diameter at therapeutic doses in patients with prior myocardial infarction.
E) Ubrogepant (an oral CGRP receptor antagonist; gepant class) is appropriate for this patient because gepants block the CGRP receptor — CLR/RAMP1 (calcitonin receptor-like receptor/receptor activity-modifying protein 1) — without activating 5-HT1B receptors on coronary or cerebral artery smooth muscle; triptans are contraindicated in patients with established ischemic heart disease, prior myocardial infarction, and Prinzmetal angina because their 5-HT1B agonist activity produces dose-dependent coronary vasoconstriction, a mechanism that gepants lack by design.
ANSWER: E
Rationale:
Triptans (sumatriptan, rizatriptan, eletriptan, zolmitriptan, and others) exert their antimigraine effect through agonism at 5-HT1B receptors on smooth muscle of intracranial and extracranial blood vessels, producing vasoconstriction that reduces dural arterial dilation during migraine attacks; 5-HT1B receptors are also expressed on coronary artery smooth muscle, and triptan-induced coronary vasoconstriction — while modest in healthy coronary arteries — poses a significant risk of ischemia in patients with fixed coronary stenoses, prior myocardial infarction, or coronary vasospasm; triptans are formally contraindicated in patients with ischemic heart disease, prior MI, cerebrovascular disease, uncontrolled hypertension, and hemiplegic or basilar migraine; gepants (ubrogepant, rimegepant, zavegepant) are CGRP receptor antagonists that block the CLR/RAMP1 receptor complex on meningeal blood vessels and trigeminal afferents without activating any serotonin receptor subtype, producing migraine relief without coronary or cerebral vasoconstriction, making them the pharmacologically appropriate acute migraine treatment for this patient with prior STEMI.
Option A: Option A is incorrect because triptans are contraindicated in all patients with established ischemic heart disease regardless of route of administration; 5-HT1B receptor-mediated coronary vasoconstriction is a class effect of all triptans at therapeutic doses and is not restricted to the intravenous formulation; the presence of dual antiplatelet therapy does not alter the direct vasoconstriction risk.
Option B: Option B is incorrect because ergotamine is contraindicated in patients with cardiovascular disease for the same reason as triptans — and more so; ergotamine is a non-selective vasoconstrictor with activity at alpha-adrenergic, 5-HT1B, and other receptors, producing prolonged and potent vasoconstriction that is particularly dangerous in patients with coronary artery disease; it is among the drugs most strongly contraindicated in patients with prior myocardial infarction.
Option C: Option C is incorrect because opioids are not recommended as first-line or preferred acute migraine therapy in any patient population per current headache guidelines; opioid use in migraine is associated with medication overuse headache, poor long-term outcomes, and systemic adverse effects; while they do not cause vasoconstriction, the guidance to use them preferentially in cardiac patients over safer, mechanism-specific alternatives such as gepants is not supported by any current guideline.
Option D: Option D is incorrect because dihydroergotamine is contraindicated in patients with ischemic heart disease; it is not coronary-safe by any route, and the claim that published cardiac catheterization data confirm no coronary arterial effect with intranasal DHE in patients with prior myocardial infarction misrepresents the available evidence and contradicts the DHE prescribing information, which lists coronary artery disease as a contraindication.
9. A 69-year-old man with decompensated heart failure is admitted with a baseline blood pressure of 104/66 mmHg. After partial response to intravenous furosemide, nesiritide is started at the standard infusion rate to reduce filling pressures. Thirty minutes into the infusion, the bedside nurse notes that his blood pressure has dropped to 82/50 mmHg. He is drowsy but arousable, with cool extremities. His heart rate is 112 bpm. Which of the following is the most appropriate immediate management?
A) Increase the nesiritide infusion rate by 50% to augment the drug's positive lusitropic effect on the left ventricle, which will improve diastolic filling and raise cardiac output, thereby restoring blood pressure through improved forward flow rather than reducing vasodilation.
B) Administer an intravenous bolus of normal saline 500 mL to restore preload; nesiritide-induced hypotension is caused by excessive venodilation reducing venous return, and fluid resuscitation is the preferred first-line intervention to restore cardiac filling pressures and correct blood pressure before considering drug discontinuation.
C) Add norepinephrine at a low dose (0.02–0.05 mcg/kg/min) to counteract nesiritide-induced vasodilation while continuing the nesiritide infusion at the current rate; the combination of vasopressor support with ongoing natriuretic peptide receptor activation maintains the hemodynamic and renal benefits of nesiritide while correcting the blood pressure deficit through alpha-1 adrenergic receptor-mediated vasoconstriction.
D) Discontinue the nesiritide infusion immediately; nesiritide's primary adverse effect is hypotension mediated by its NPR-A (natriuretic peptide receptor A)-cGMP vasodilatory mechanism, and a systolic blood pressure of 82 mmHg with signs of reduced perfusion (drowsiness, cool extremities) constitutes clinically significant drug-induced hypotension requiring cessation of the offending agent; once the infusion is stopped, nesiritide's effects will dissipate over its approximately 18-minute half-life, allowing blood pressure to recover.
E) Reduce the nesiritide dose by 25% and administer a 250 mL normal saline bolus; dose reduction combined with volume supplementation is the preferred stepwise approach to nesiritide-associated hypotension, and the drug should only be discontinued entirely if blood pressure fails to recover above 90 mmHg after two consecutive dose reductions.
ANSWER: D
Rationale:
Nesiritide's mechanism of action — NPR-A-mediated cGMP generation causing venodilation and arterial vasodilation — is also the mechanism of its primary adverse effect; hypotension is the most clinically significant and most commonly encountered complication of nesiritide infusion, and it is more likely and more severe in patients with borderline perfusion pressures at baseline; a blood pressure of 82/50 mmHg with associated signs of hypoperfusion (drowsiness, cool extremities) in a patient who started at 104/66 mmHg represents a clinically significant hemodynamic deterioration that requires immediate discontinuation of the vasodilating agent; nesiritide has a short half-life of approximately 18 minutes, and cessation of the infusion allows plasma levels to decline rapidly, with most patients recovering blood pressure within 30–60 minutes of stopping the drug; in the meantime, supportive measures including fluid administration and, if needed, vasopressor support can be considered based on clinical response.
Option A: Option A is incorrect because increasing the nesiritide infusion rate would worsen the already-significant hypotension by amplifying the cGMP-mediated vasodilatory effect; nesiritide has no clinically meaningful positive lusitropic activity that would independently restore cardiac output in this situation, and dose escalation of the offending vasodilator is directly contraindicated in the setting of drug-induced hemodynamic compromise.
Option B: Option B is incorrect because while fluid administration may have a role as a supportive measure, it does not constitute the most appropriate immediate management step — which is discontinuation of the drug causing the hypotension; continuing nesiritide while giving fluid boluses without stopping the offending agent delays the primary corrective action and may be insufficient to restore blood pressure given ongoing vasodilatory drug effect.
Option C: Option C is incorrect because continuing nesiritide while adding vasopressor support is not the recommended approach to nesiritide-induced hypotension; the combination exposes the patient to the risks of vasopressor therapy without eliminating the cause of hemodynamic compromise, and the established management of nesiritide-induced hypotension is drug discontinuation rather than pharmacological blood pressure rescue while maintaining the infusion.
Option E: Option E is incorrect because a stepwise dose-reduction approach is not appropriate when the patient has already developed clinically significant hypotension with signs of hypoperfusion; a systolic of 82 mmHg with drowsiness and cool extremities requires immediate drug discontinuation rather than a titration protocol; the 25% dose reduction strategy described is not supported by the nesiritide prescribing information as the first response to symptomatic hypotension.
10. A 61-year-old man with HFrEF (ejection fraction 30%) was transitioned from lisinopril to sacubitril-valsartan 6 weeks ago after developing an intolerable dry cough on the ACE (angiotensin-converting enzyme) inhibitor. Three weeks after starting sacubitril-valsartan he reports a mild but bothersome dry cough that is less severe than his previous lisinopril cough. The patient asks why he is coughing again on a drug that "is not an ACE inhibitor." Which of the following best explains the mechanism of cough with sacubitril-valsartan and why it is less severe than with lisinopril?
A) Valsartan, the ARB (angiotensin receptor blocker) component of sacubitril-valsartan, partially blocks AT2 receptors (angiotensin type 2 receptors) in bronchial epithelium at high therapeutic concentrations; AT2 receptor blockade stimulates bradykinin synthesis in airway mast cells through a counter-regulatory mechanism, producing cough at a lower intensity than ACE inhibitor-mediated cough because only the minority AT2 receptor subtype is affected rather than the predominant AT1 receptor.
B) Sacubitril inhibits neprilysin, which is one of the enzymes responsible for bradykinin degradation; bradykinin accumulation from neprilysin inhibition stimulates B2 receptors on sensory C-fibers in the bronchial mucosa, producing cough; the cough is less severe than with lisinopril because ACE (kininase II) remains fully functional — providing an intact alternative degradation pathway for bradykinin — so the degree of bradykinin accumulation is lower than when ACE itself is blocked, which eliminates the primary bradykinin degradation pathway entirely.
C) Sacubitril competitively inhibits ACE at submaximal concentrations during peak plasma levels, producing transient and partial kininase II blockade that is responsible for cough; the cough is less severe than lisinopril because sacubitril's ACE inhibition is reversible and concentration-dependent, with trough plasma levels producing no ACE inhibition and therefore no bradykinin accumulation during the low-drug phase of the dosing interval.
D) Elevated BNP levels during sacubitril-valsartan therapy stimulate NPR-A receptors in bronchial submucosal glands, increasing mucus secretion and cough reflex sensitivity through a cGMP-dependent mechanism; the cough is less severe than ACE inhibitor cough because BNP-mediated NPR-A activation produces a weaker cough reflex amplification than the direct bradykinin B2 receptor stimulation produced by kininase II blockade with lisinopril.
E) Substance P, a neprilysin substrate that accumulates when sacubitril inhibits neprilysin, is the sole mediator of cough with sacubitril-valsartan; substance P stimulates NK1 receptors on bronchial C-fibers to produce cough; the cough is less severe than with lisinopril because lisinopril causes both bradykinin and substance P accumulation through dual kininase II inhibition, whereas sacubitril raises only substance P without any bradykinin increase, as ACE remains fully functional and degrades all bradykinin produced during sacubitril therapy.
ANSWER: B
Rationale:
Neprilysin (neutral endopeptidase 24.11) degrades multiple vasoactive peptides including bradykinin, substance P, ANP, BNP, and adrenomedullin; when sacubitril inhibits neprilysin, bradykinin clearance through this pathway is impaired and bradykinin accumulates; elevated bradykinin activates B2 receptors on sensory C-fibers in the bronchial epithelium and submucosa, triggering the cough reflex; this is the same mechanism responsible for ACE inhibitor cough, but with an important quantitative difference — ACE (kininase II) is the primary enzyme responsible for bradykinin degradation, and when ACE is inhibited by lisinopril, the dominant clearance pathway is blocked, producing substantial bradykinin accumulation; with sacubitril, ACE remains fully functional as a bradykinin-degrading enzyme, providing an intact alternative clearance pathway that limits the degree of bradykinin accumulation to a lower level than with ACE inhibition, explaining why sacubitril-valsartan cough is less severe and occurs in fewer patients than ACE inhibitor cough.
Option A: Option A is incorrect because valsartan does not block AT2 receptors; valsartan is a selective AT1 receptor antagonist, and AT2 receptor blockade is not part of its mechanism; furthermore, the mechanism of ARB-associated cough is minimal because ARBs do not affect bradykinin metabolism — the low cough rate with ARBs compared with ACE inhibitors is precisely because they do not impair bradykinin degradation.
Option C: Option C is incorrect because sacubitril does not inhibit ACE; sacubitril inhibits neprilysin (neutral endopeptidase 24.11), which is a structurally and mechanistically distinct enzyme; ACE inhibition is the mechanism of lisinopril and other ACE inhibitors, and sacubitril has no meaningful ACE inhibitory activity at any therapeutic plasma concentration.
Option D: Option D is incorrect because elevated BNP stimulating NPR-A in bronchial submucosal glands to increase mucus secretion is not a recognized mechanism of cough in sacubitril-valsartan-treated patients; cGMP generated by natriuretic peptide receptor activation in the airway has not been established as a mediator of cough, and BNP-NPR-A signaling does not produce the dry non-productive cough characteristic of bradykinin-mediated airway C-fiber stimulation.
Option E: Option E is incorrect because it misstates the relative contribution of bradykinin and substance P; both bradykinin and substance P are neprilysin substrates and both accumulate during sacubitril therapy, but bradykinin is the primary mediator of ACE inhibitor-type cough, not substance P alone; the claim that sacubitril raises only substance P without any bradykinin increase — because ACE degrades all bradykinin — is incorrect because neprilysin contributes meaningfully to bradykinin clearance independent of ACE, and partial neprilysin inhibition does produce bradykinin accumulation above baseline.
11. A 67-year-old man with decompensated heart failure is admitted with volume overload. An echocardiogram confirms severely elevated left atrial pressure and a dilated right atrium. A medical student asks the attending physician why the patient's kidneys are not simply excreting the excess sodium and fluid on their own, given that the heart is producing large amounts of ANP (atrial natriuretic peptide; a 28-amino-acid peptide released by atrial myocytes in response to atrial wall stretch). The physician explains that ANP does have a natriuretic effect but that it is overwhelmed by counterregulatory neurohumoral activation in decompensated heart failure. Which of the following correctly describes the mechanism by which ANP produces natriuresis at the kidney?
A) ANP binds to Gs-coupled GPCRs (G protein-coupled receptors linked to stimulatory G proteins) on renal proximal tubule cells, increasing intracellular cAMP (cyclic adenosine monophosphate) through adenylyl cyclase activation; elevated cAMP activates protein kinase A, which phosphorylates and activates the Na-K-2Cl cotransporter (NKCC2) in the thick ascending limb of Henle, increasing sodium reabsorption and generating a concentrated medullary gradient that paradoxically promotes water retention despite the high ANP levels.
B) ANP binds to NPR-B (natriuretic peptide receptor B; the receptor for CNP [C-type natriuretic peptide]) on glomerular mesangial cells, causing mesangial cell relaxation and an increase in the filtration surface area available for glomerular filtration; the increased filtration surface produces a pressure-independent rise in GFR (glomerular filtration rate), generating greater tubular sodium delivery that overwhelms reabsorptive capacity and produces natriuresis through a purely filtration-dependent mechanism.
C) ANP binds to NPR-A (natriuretic peptide receptor A; a transmembrane guanylyl cyclase) on renal tubular cells and glomerular mesangial cells, stimulating intracellular cGMP (cyclic guanosine monophosphate) production; cGMP activates protein kinase G (PKG), which inhibits sodium reabsorption in the inner medullary collecting duct by reducing the activity of the epithelial sodium channel (ENaC) and the Na-K-ATPase, while simultaneously promoting afferent arteriolar dilation and efferent arteriolar constriction to increase the glomerular filtration rate and filtered sodium load; the net effect is increased urinary sodium excretion and diuresis.
D) ANP binds to NPR-C (natriuretic peptide receptor C; the clearance receptor expressed on renal vascular endothelium) and is internalized and degraded by the receptor; this receptor-mediated clearance in the kidney rapidly removes circulating ANP from the portal circulation before it can reach tubular cells, explaining why endogenous ANP is ineffective at producing natriuresis despite elevated plasma levels in decompensated heart failure and why exogenous nesiritide must be administered at supraphysiological doses to overcome this renal clearance mechanism.
E) ANP acts through soluble guanylyl cyclase (sGC; the cytoplasmic enzyme activated by nitric oxide) rather than through membrane-bound NPR-A in renal tubular cells; the sGC pathway generates cGMP that activates phosphodiesterase type 5 (PDE5), rapidly degrading cGMP before it can inhibit sodium reabsorption; this intrinsic cGMP degradation mechanism limits ANP's natriuretic effect in the kidney, which is why PDE5 inhibitors such as sildenafil enhance the natriuretic response to endogenous ANP in heart failure patients.
ANSWER: C
Rationale:
ANP (atrial natriuretic peptide) exerts its renal effects by binding to NPR-A on renal tubular cells, glomerular endothelial cells, and mesangial cells; NPR-A is a transmembrane receptor with intrinsic guanylyl cyclase activity that converts GTP to cGMP upon ANP binding; cGMP then activates protein kinase G (PKG), which phosphorylates multiple downstream targets in the nephron — most importantly, PKG inhibits the epithelial sodium channel (ENaC) in the inner medullary collecting duct, reduces Na-K-ATPase activity, and suppresses aldosterone-stimulated sodium reabsorption; simultaneously, ANP causes afferent arteriolar dilation (increasing glomerular hydrostatic pressure and GFR) and efferent arteriolar constriction (further increasing filtration fraction), increasing the filtered sodium load delivered to tubular segments; the combined effect of increased filtered load and reduced reabsorption produces natriuresis and diuresis; in decompensated heart failure, this intrinsic natriuretic response is overwhelmed by RAAS activation, elevated aldosterone, sympathetic nervous system activation, and reduced renal perfusion pressure — explaining the clinical paradox of elevated ANP with persistent sodium retention.
Option A: Option A is incorrect because ANP does not signal through Gs-coupled GPCRs or generate cAMP; NPR-A is a receptor guanylyl cyclase — not a GPCR — and generates cGMP rather than cAMP; the Na-K-2Cl cotransporter (NKCC2) activation described in this option produces sodium reabsorption (the mechanism of loop diuretic targets), which is the opposite of the natriuretic effect attributable to ANP.
Option B: Option B is incorrect because ANP acts through NPR-A, not NPR-B; NPR-B is the receptor for CNP (C-type natriuretic peptide), not ANP or BNP; while ANP does have modest effects on mesangial cell relaxation contributing to increased GFR, this alone does not account for its natriuretic action, which is primarily mediated through tubular sodium reabsorption inhibition via the NPR-A-cGMP-PKG pathway.
Option D: Option D is incorrect because NPR-C, while a clearance receptor, does not exclusively account for ANP's ineffectiveness in decompensated heart failure; ANP does reach renal tubular cells and activates NPR-A in the kidney — the reason endogenous ANP fails to overcome sodium retention in heart failure is neurohumoral counter-regulation (RAAS, aldosterone, sympathetic activation), not rapid renal clearance; furthermore, this option's characterization of NPR-C function does not explain why nesiritide requires supraphysiological doses, as the doses used clinically are within a pharmacological rather than supraphysiological range.
Option E: Option E is incorrect because ANP does not act through soluble guanylyl cyclase (sGC); sGC is activated by nitric oxide, not by natriuretic peptides; ANP acts exclusively through the membrane-bound NPR-A guanylyl cyclase, and the claim that ANP-generated cGMP activates PDE5 (which degrades cGMP) rather than PKG inverts the actual signal transduction pathway.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.